GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

Their core work

GSK R&D is the research and development arm of GlaxoSmithKline, one of the world's largest pharmaceutical companies, focused on drug discovery, clinical trials, and translational medicine. Within H2020, they contribute industry-scale clinical data, compound libraries, and drug development infrastructure to large public-private consortia — particularly in immunology, autoimmune diseases, anti-infectives, and pediatric medicine. They bring real-world pharmaceutical pipeline expertise to academic-led projects, enabling translational research that bridges laboratory discoveries and patient outcomes. Their participation spans from early-stage drug target identification (ubiquitin ligases, protein-protein interactions) through to clinical trial design and pharmacovigilance.

What they specialise in

How they've shifted over time

In the early period (2015–2017), GSK R&D engaged broadly across foundational pharmaceutical R&D — adaptive trial design (ADAPT-SMART), type 1 diabetes biomarkers (INNODIA), inflammatory bowel disease epigenetics (EPIMAC), and computational chemistry training networks (TCCM, FRAGNET). From 2018 onward, their focus sharpened toward data-intensive drug development: federated machine learning for drug discovery (MELLODDY), FAIR data infrastructure (FAIRplus), predictive modelling for pharmacovigilance (ConcePTION), and precision immunology with multi-omics approaches (IMMUcan, 3TR). The shift reflects a clear move from traditional pharma R&D participation toward computational, data-sharing, and AI-augmented drug development.

GSK R&D is increasingly investing in AI/ML-powered drug discovery, federated data sharing, and precision immunology — expect future collaborations to center on computational approaches to treatment stratification and safety prediction.

How they like to work

GSK R&D exclusively participates as a partner or third party — never as coordinator — which is typical for large pharma in IMI and H2020 consortia where academic or SME leads are preferred. They operate in very large consortia (649 unique partners across 34 countries), contributing proprietary data, compound access, and clinical infrastructure rather than leading project management. This makes them a reliable industry anchor partner who brings scale and real-world pharmaceutical assets without competing for project leadership.

GSK R&D has collaborated with 649 unique partners across 34 countries, making them one of the most broadly connected pharmaceutical industry participants in H2020. Their network spans virtually all EU member states plus associated countries, with particularly strong ties to academic medical centers and other pharma companies through IMI-funded consortia.

What sets them apart

As one of the top-3 global pharmaceutical companies, GSK R&D brings assets that few partners can match: proprietary compound libraries, global clinical trial networks, real-world patient data, and regulatory submission experience. Unlike smaller biotech partners, they can carry projects from target identification through Phase III trials and into market. Their willingness to engage in open-innovation consortia — including data-sharing initiatives like MELLODDY and FAIRplus — signals an unusually open posture for Big Pharma, making them an attractive partner for academics seeking industry translation paths.

Highlights from their portfolio

• MELLODDY
  Pioneering federated machine learning across 10 pharma companies to train shared predictive models on proprietary drug discovery data without exposing it — a first-of-its-kind privacy-preserving collaboration.
• c4c
  Major 8-year initiative (2018–2025) building a pan-European pediatric clinical trial network, addressing one of pharma's most persistent gaps: drug development for children.
• 3TR
  Large-scale multi-disease project (2019–2026) tackling treatment non-response across autoimmune and inflammatory conditions using multi-omics stratification — directly relevant to GSK's immunology pipeline.